A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody) in Patients With Solid Tumors
1/2상
조기 종료
NCT05159388
| 대상 질환 | Solid Tumor |
|---|
| 임상 단계 | 1/2상 |
|---|
| 스폰서 | Servier Bio-Innovation LLC |
|---|
| 상태 | 조기 종료 |
|---|
| 참여자 수 | 46 명 |
|---|
| 중재(약물) | PRS-344/S095012 |
|---|
| 시작일 | 2021년 9월 8일 |
|---|
| 완료일 | 2025년 4월 1일 |
|---|
| 결과 공개일 | 2026년 6월 16일 |
|---|
요약
This is a first-in-human (FIH), phase 1/2, multi center, open-label, dose escalation and cohort expansion study designed to determine the safety and tolerability of PRS-344/S095012 in patients with advanced and/or metastatic solid tumors.
Safety Measurements: Number of Participants With at Least One DLT in the First 28-days of Treatment
28 days · Participants
| PRS-344/S095012 12mg | 0 Participants |
|---|
| PRS-344/S095012 36mg | 1 Participants |
|---|
| PRS-344/S095012 60mg | 3 Participants |
|---|
| PRS-344/S095012 80mg | 1 Participants |
|---|
| PRS-344/S095012 36mg and Obinutuzumab | 3 Participants |
|---|
Safety Measurements: Number of Participants With at Least One AE
Through study termination, approximately 3.5 years · Participants
| PRS-344/S095012 12mg | 4 Participants |
|---|
| PRS-344/S095012 36mg | 9 Participants |
|---|
| PRS-344/S095012 60mg | 14 Participants |
|---|
| PRS-344/S095012 80mg | 6 Participants |
|---|
| PRS-344/S095012 36mg and Obinutuzumab | 12 Participants |
|---|
Safety Measurements: Number of Participants With at Least One AE Leading to Treatment Discontinuation
Through study termination, approximately 3.5 years · Participants
| PRS-344/S095012 12mg | 1 Participants |
|---|
| PRS-344/S095012 36mg | 4 Participants |
|---|
| PRS-344/S095012 60mg | 7 Participants |
|---|
| PRS-344/S095012 80mg | 2 Participants |
|---|
| PRS-344/S095012 36mg and Obinutuzumab | 7 Participants |
|---|
BENITIONS에서 보기
ClinicalTrials.gov 원문 보기
전체 임상
이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.